David Tomasso Email & Phone Number

Raleigh-Durham, North Carolina Area

The principals of Lighthouse BioPartners are licensed investment banking agents, offering securities through M&A Securities Group, Inc., an unaffiliated broker-dealer, Member FINRA/SIPC. Any third-party posts linked to this profile should not be considered to represent my views or the views of Lighthouse BioPartners or M & A Securities Group, Inc.Partnering and financial advisory for the life sciences+ Located outside Research Triangle Park in Raleigh, NC+ Focus on business development, licensing, partnership transactions and investor financing services+ Expertise in large pharma, specialty pharma, diagnostics and biotech as well as biotech start-up environmentsProject Focus:+ Corporate and project financing+ In-licensing and out-licensing transactions for marketed products and development stage assets+ Business Development process management – outreach strategy, contact engagement, due diligence, transaction execution

Greater New York City Area

Torreya Insights is a rapidly growing data and consulting services company focused on pharmaceutical business development. Our work has taken place in pharmaceuticals, biotechnology, medical technology, diagnostics, nutritionals, pharma services and closely related sectors. The company is involved in the production of an online compilation of available pharmaceutical business development opportunities called AvaRx. Also available are business development and financing solutions software called Licensing Dynamics and Financing Dynamics. Torreya Insights is also frequently involved in providing consulting services in the areas of in-licensing, out-licensing and financing linked to these software products.Its parent company, Torreya Partners, is a leading corporate finance advisory boutique serving companies in the life sciences industry. We have successfully completed more than a 100 assignments since we started in August 2007.Torreya has its primary offices in London and New York and through its affiliate Torreya Emerging Markets also has partners in Mexico City, Rio de Janeiro, Hong Kong, Riyadh, and Johannesburg. Torreya is also affiliated with a number of partner advisory firms in Eastern Europe and Asia.We are a partner of choice for companies seeking discreet, unconflicted and knowledgeable advice on M&A, corporate finance, licensing and asset sale transactions. In some cases, Torreya Partners acts as a pure advisor on a retained basis to its clients.

Greater San Diego Area

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products for the diabetes, oncology, dermatology, and drug delivery markets. The company's product portfolio is primarily based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix.Responsible for partnering proprietary programs and identifying new technologies for R&D collaboration.* Responsible for business development, financial evaluation, due diligence and negotiations.* Board member for international entity, Halozyme Holdings Ltd.* Leading partnering effort for ultrafast insulin co-formulation to treat T1DM and T2DM.* Leading partnering effort for novel therapeutic to treat cellulite in aesthetics market.* Led partnering process for most advanced asset in company portfolio, a novel pegylated enzyme for treating solid tumors (i.e. pancreatic, breast, prostate, lung, colorectal and other cancer types).* Negotiating R&D collaborations for technologies to enhance efficiency of manufacturing processes.

Austin, Texas Area

Genprex is a clinical-stage biopharmaceutical company developing cancer therapeutics. Oncoprex®, our lead product candidate, is a novel, pan-kinase inhibitor that works to induce apoptosis in cancer cells and control cell signaling and inflammatory pathways to treat cancer at the molecular level without harming normal cells.Responsible for manufacturing, fundraising, business development, and corporate finance.* Responsible for identifying contract manufacturing organization and negotiating definitive agreement.* Identified potential investment partners with angel groups, venture capital and alternative financing.

Austin, Texas Area

Madison, Wisconsin Area

Responsible for out-licensing, due diligence and financial evaluation of potential R&D collaborations, commercial partnerships and licensing agreements for novel drug delivery systems.* Responsible for corporate development, alliance management, corporate finance and accounting.* Identified potential partners at pharmaceutical and biotechnology companies in US and Europe, preparing targeted product lists, initiating contact and negotiating agreements. * Conducted corporate finance activities in preparation for private equity financing.

Cary, Nc

Responsible for sourcing, due diligence and financial evaluation of potential acquisitions, partnerships and licensing agreements.* Negotiated in-licensing, acquisition and co-promotion arrangements with companies in US and Europe. * Responsible for evaluating in-licensing opportunities primarily in pain and pain related therapeutic areas but also in neurology, psychology, antivirals and drug delivery.

Responsible for sourcing, due diligence and financial evaluation of potential partnerships and licensing agreements.* Negotiated out-licensing, in-licensing and co-promotion arrangements with companies in US, Europe and Japan. * Responsible for evaluating in-licensing opportunities primarily in hospital/acute care and neuroscience but also in respiratory, cardiovascular, metabolics and drug delivery.* Appointed Alliance Manager responsibility for several consummated partnerships.

West Point, Pa

Responsible for sourcing, due diligence and financial evaluation of potential partnerships.* Lead negotiator in licensing and distribution arrangements with major companies, including Chiron, Baxter, Amgen. * Led evaluation of domestic and international partnerships in US, Japan, Australia, Latin America, Canada and Eastern Europe. Recommended distribution strategies for the Philippines, New Zealand, Taiwan and Korea. * Negotiated distribution agreement in Japan for M-M-R®II. Negotiated additional terms in Japan for use of the varicella virus in Merck’s quadravalent and PHN vaccines, and determined Merck’s rights to new markets.* Coordinated the effort to access new technologies to supplant other stabilizers in our live virus vaccines. Evaluated new delivery device and adjuvant technologies for entire vaccine line.

Hospital Representative – Cardiovascular: Merck Human Health 1998-2000, Bronx, NYCharged with development, implementation and management of strategic initiatives to reverse negative sales trends in high-volume, strategic district.* Received the Vice President’s Award for contribution to the progress of the division and the medical community, for achieving 123% PPO and attaining exceptional MBO performance during 2000.* Increased sales of Zocor® from $650,000 (63% share) to $1.1 million (85% share).* Led district in %PPO for Aggrastat®, Cozaar® and Vioxx®; ranked second for Zocor®.Senior GPO Customer Manager: Merck Vaccine Division 1996-1998 West Point, PA Recommended and implemented strategy based on a refined business model focusing efforts in the customer segment on improved customer support and divisional profitability. Supported marketing teams across product lines and devised integrated program to maximize sales. Developed, negotiated and implemented contracts with Group Purchasing Organizations (GPO) including Novation, Premier, and AmeriNet.Live Virus Vaccine Core Team Manager: Merck Vaccine Division 1995-1996 West Point, PA As member of business development function, chartered with task of defining strategic vision for multiple antigens within the live virus family including: measles, mumps, rubella, varicella, zoster and rotavirus. Managed a senior level, cross-functional business team responsible for the development and implementation of detailed product family strategic plans, resource allocation, and competitive assessments. Facilitated communications with Merck Vaccine Business Leadership Team with representation from manufacturing, marketing and research.Promotion Manager: 1995 Merck Vaccine Division West Point, PADevelopmental assignment to introduce the nuances of the marketing organization in anticipation of transition to cross-functional leadership.

Senior Projects Planner: 1990-1995 Merck Manufacturing Division West Point, PACharged with leading the vaccine manufacturing team during pre-launch and launch phases of new varicella vaccine introduction.Lyo Operations Production Supervisor: 1988-1990 Merck Manufacturing Division West Point, PAGained valuable leadership experience in a highly technical and specialized industrial environment. Supervised 30 union employees who performed filling, lyophilization, sealing and inspection of biological products.Biological Quality Control Inspector/Auditor: 1986-1988 Merck Manufacturing Division West Point, PATrained in evaluating internal and external manufacturing processes and learned first-hand the rigorous cGMP requirements mandated by the US FDA and international regulatory agencies.

Mba, Finance

Master'S Degree, Manufacturing Systems Engineering, Gpa: 3.3

Bachelor'S Degree, Biology/Biological Sciences, General, Gpa: 3.3